株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

内臓痛覚:パイプライン製品の分析

Visceral Pain - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 283207
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
内臓痛覚:パイプライン製品の分析 Visceral Pain - Pipeline Review, H2 2017
出版日: 2017年08月16日 ページ情報: 英文 55 Pages
概要

内臓痛覚とは、内臓から発生する侵害受容性疼痛の一種です。主な症状には、うずくような痛み(疼痛)や締め付けられるような痛み、拡散するような痛みなどが挙げられます。主な治療薬には、鎮痛剤(麻酔・NSAID(非ステロイド系抗炎症性薬物)等)や疼痛重合調整剤(三環系抗うつ剤・抗けいれん薬等)などがあります。

当レポートでは、世界各国での内臓痛覚治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

内臓痛覚の概要

治療薬の開発

  • 内臓痛覚向けパイプライン製品:概要
  • 内臓痛覚向けパイプライン製品:比較分析

各企業で開発中の内臓痛覚治療薬

各大学/研究機関で研究中の内臓痛覚治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

内臓痛覚治療薬:開発中の製品の一覧(企業別)

内臓痛覚治療薬:研究中の製品の一覧(大学/研究機関別)

内臓痛覚治療薬の開発に従事している企業

  • Addex Therapeutics Ltd
  • アステラス製薬
  • Chromocell Corporation
  • GIcare Pharma Inc
  • Grunenthal GmbH
  • Medestea Research & Production S.p.A.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.

内臓痛覚:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

内臓痛覚治療薬:休止中のプロジェクト

内臓痛覚治療薬:開発が中止された製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9620IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Visceral Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Visceral Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Visceral Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Visceral Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Visceral Pain (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Visceral Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Visceral Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Visceral Pain - Overview
    • Visceral Pain - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Visceral Pain - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Visceral Pain - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Anavex Life Sciences Corp
    • Arena Pharmaceuticals Inc
    • BELLUS Health Inc
    • Cadila Healthcare Ltd
    • Chromocell Corp
    • Eli Lilly and Company
    • Grunenthal GmbH
    • Medestea Research & Production SpA
    • Pfizer Inc
  • Visceral Pain - Drug Profiles
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANAVEX-1066 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-8464 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HS-665 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NXN-677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBFI-26 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WITH-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYKR-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Visceral Pain - Dormant Projects
  • Visceral Pain - Discontinued Products
  • Visceral Pain - Product Development Milestones
    • Featured News & Press Releases
      • Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Visceral Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Visceral Pain - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Visceral Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Visceral Pain - Pipeline by BELLUS Health Inc, H2 2017
  • Visceral Pain - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Visceral Pain - Pipeline by Chromocell Corp, H2 2017
  • Visceral Pain - Pipeline by Eli Lilly and Company, H2 2017
  • Visceral Pain - Pipeline by Grunenthal GmbH, H2 2017
  • Visceral Pain - Pipeline by Medestea Research & Production SpA, H2 2017
  • Visceral Pain - Pipeline by Pfizer Inc, H2 2017
  • Visceral Pain - Dormant Projects, H2 2017
  • Visceral Pain - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Visceral Pain - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Visceral Pain, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top